Dec 22 2009
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an update to the
preliminary revenue and adjusted earnings per share growth rate guidance
provided to investors at the Company’s recent analyst R&D day meeting on
December 3, 2009. The Company now believes that the 2010 overall revenue
percentage growth rate will be in the mid-teens and re-affirms that
adjusted earnings per share will grow at 10% or more.
“We believe it is important for us to provide investors with some
preliminary quantification of the relatively limited potential financial
impact of last week’s surprising ODAC meeting”
“We believe it is important for us to provide investors with some
preliminary quantification of the relatively limited potential financial
impact of last week’s surprising ODAC meeting,” stated Colin Goddard,
Chief Executive Officer of OSI Pharmaceuticals. “Even assuming a
scenario where we are unable to secure any label expansion from the
ongoing sNDA application for Tarceva based on the SATURN study, we
believe the business will continue to exhibit solid growth in 2010 with
an overall revenue growth rate in the mid-teens (percentage wise) –
broadly in-line with the ranges communicated to investors at our recent
research analyst meeting in early December.”
The Company also provided investors with an update on the re-purchase of
a portion of its outstanding convertible debt bonds. As of December 22,
2009, the Company had purchased $39.5 million face value of the 2023
convertible bonds for $37.6 million and $40.0 million face value of the
2038 convertible bonds for $37.4 million. The aggregate amount of the
Company’s outstanding 2038 Notes, 2023 Notes and 2025 Notes at face
value is now equal to $335.5 million. The Company may, from
time-to-time, continue to selectively re-purchase convertible debt bonds
and common stock throughout 2010.